Acrivon Therapeutics, INC Form 4 insider transactions

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, reports disposing of 403 shares to cover tax obligations related to vesting restricted stock units.

Eric Devroe, COO of Acrivon Therapeutics, disposed of 613 shares to cover tax obligations related to vesting restricted stock units.

Peter Blume-Jensen, President and CEO, and Kristina Masson, EVP Business Operations, report changes in their beneficial ownership of Acrivon Therapeutics, Inc. stock due to tax withholding upon vesting of restricted stock units.

Perceptive Advisors LLC, along with related entities, sold shares of Acrivon Therapeutics (ACRV) at weighted average prices of $1.41 and $1.34, reducing their holdings.

Perceptive Advisors LLC, along with related entities, sold shares of Acrivon Therapeutics (ACRV) between April 25 and April 29, 2025.

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports the disposal of 558 shares of common stock to cover tax obligations upon vesting of restricted stock units.

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, acquires stock options for 15,616 shares of common stock.

Adam D. Levy, CFO of Acrivon Therapeutics, reports the acquisition of stock options.

Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, reports the acquisition of stock options.

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, acquired stock options for 93,693 shares of common stock on March 1, 2025.

Rasmus Holm-Jorgensen, CFO of Acrivon Therapeutics, reports the acquisition of stock options on March 1, 2025.

Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, reports acquisition of stock options.

Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, acquired stock options for 140,540 shares on March 1, 2025.

Jean-Marie Cuillerot, Chief Medical Officer of Acrivon Therapeutics, received stock options for 78,078 shares on March 1, 2025.

Acrivon Therapeutics' President/CEO Peter Blume-Jensen and EVP Kristina Masson report exercising stock options, with vesting schedules extending to February 2035.

Acrivon Therapeutics' President/CEO Peter Blume-Jensen and EVP Kristina Masson report changes in their beneficial ownership of company stock due to tax withholding upon vesting of restricted stock units.

Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports the disposition of shares to cover tax obligations upon vesting of restricted stock units.

Rasmus Holm-Jorgensen, CFO of Acrivon Therapeutics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Chief Development Officer Erick Gamelin of Acrivon Therapeutics reports a transaction involving common stock to cover tax obligations.

Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, reports disposing of shares to cover tax withholding requirements upon vesting of restricted stock units.

Peter Blume-Jensen and Kristina Masson, executives at Acrivon Therapeutics, report changes in their beneficial ownership of company stock due to tax withholding upon vesting of restricted stock units.

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, was granted stock options for 67,567 shares on March 1, 2024.

Acrivon Therapeutics' Chief Financial Officer, Rasmus Holm-Jorgensen, was granted stock options for 90,090 shares on March 1, 2024.

Erick Gamelin, Chief Development Officer at Acrivon Therapeutics, was granted stock options for 45,045 shares on March 1, 2024.

Acrivon Therapeutics' Chief Operating Officer, Eric Devroe, was granted stock options for 90,090 shares at an exercise price of $5.70 on March 1, 2024.

Acrivon Therapeutics' CEO and EVP of Business Operations were granted stock options, with vesting schedules tied to continued service.

Acrivon Therapeutics' President and CEO, Peter Blume-Jensen, and EVP of Business Operations, Kristina Masson, reported transactions involving company stock, including shares withheld for tax obligations and indirect holdings.